RSS Feeds
Ezetimibe and Statin-Associated Myopathy
- Richard Fux, MD;
- Klaus Mörike, MD;
- Udo-Frank Gundel, MD;
- Rüdiger Hartmann, MD; and
- Christoph H. Gleiter, MD
- From Tübingen, Reutlingen, and Münsingen, Germany.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Ezetimibe, a recently approved inhibitor of intestinal cholesterol absorption, may be added to a statin to improve control of hypercholesterolemia, although it is also licensed for monotherapy (10 mg/d). While statins carry …
